Sixteen Yorkshire swine weighing 15-20 kg were studied to compare the effects of suxamethonium, atracurim and vecuronium on intracranial pressure (ICP), heart rate (HR), arterial blood pressure (BP), and cerebral perfusion pressure (CPP) in swine with normal or elevated ICP. In each animal an intacranial pressure-volume curve was produced by the inflation of an epidural balloon. The baseline ICP (P d, the [CP at the inflection point (PJ and on the steep portion (PmaxJ of the pressure-volume curve were identified and the balloon volumes recorded. The animals were assigned to receive either suxamethonium 1.0 mglkg, atracurium 0.6 mglkg, vecuronium 0.2 mglkg, or saline placebo intravenously at three conditions: First, with the epidural balloon deflated Pa, next at Pi, then at P max . Neither atracurium, vecuronium, nor placebo produced any statisticially significant effect on HR, BP, [CP, or CPP at any baseline level of [CP. Suxamethonium produced an early fall in [CP (0.8 ± 0.3, 2.6 ± 1.0 and 3.5 ±1.3 mmHg at P a, Pi and P max respectively: P = .0005) followed by a rapid rise above the pre-infusion level (1.8 ± 0.6, 2.8± 0.6 mmHg, and 2.2± 0.5 mmHgatP a , Pi andP max respectively: P= .0005). Afall in BP coupled with the rise in [CP resulted in afall in CPP (5.8 ± 2.3, 6.1 ± 1.2, and 6.3 ± 1.8 mmHg at Pa, Pi and P max respectively: P= .0005). Although thefall in CPP was not large, in the presence of elevated [CP, where CPP already is marginal, such a decrease may compromise cerebral blood flow. Atracurium and vecuronium had no effect on [CP or haemodynamics, even in the presence of an elevated [CP. These agents may be preferred in settings of suboptimal CPP or in the presence of pre-existing intracranial hypertension.
instituting neuromuscular blockade in high risk neurosurgical patients is widely debated. Several studies both in animals l -2 and in man 3 -6 have demonstrated a significant effect of suxamethonium in raising ICP. Further, this effect may be exaggerated in the presence of an elevated baseline ICPY Conversely, suxamethonium produces minimal haemodynamic changes. 7 The ICP rise probably reflects increased cerebral blood flow (CBF) induced by enhanced cerebral electrical activity and carbon dioxide production. 2 Worsening of ICP and CPP following suxamethonium administration does occur, although the likelihood of an adverse clinical consequence of a brief elevation of ICP can be argued. 8 The newer nondepolarising neuromuscular blockers, vecuronium and atracurium, provide rapid and safe muscle relaxation. Complete blockade is achieved in 90 seconds following a standard intubating dose of 0.2 mg/kg for vecuronium or 0.6 mg/kg for atracurium. 9 'priming dose' three to four minutes prior to the full intubating dose of vecuronium or atracurium. 9 • 11 Except in cases where the airway is compromised acutely, the few seconds advantage which suxamethonium provides probably is unnecessary. Any benefit may be offset if elevated ICP is known or suspected. Although the effect of administering these newer agents on ICP and CPP has been described,12-14 controlled studies comparing atracurium and vecuronium with suxamethonium have not been performed. Atracurium does not produce significant changes in the ICP or (14) 70 (12) haemodynamics in neurosurgical patients. However, previous reports do not separate patients with normal ICP from those with elevated ICP. Herein we compare the effects of vecuronium and atracurium with suxamethonium and placebo on ICP, arterial blood pressure (BP), cerebral perfusion pressure (CPP), and heart rate (HR) in swine with normal ICP or with intracranial hypertension induced by an epidural balloon in a randomised, blinded experiment.
MATERIALS AND METHODS
and (4) normal saline 3 ml (n = 4). The investigators were blinded to the identity of the agent being administered. Adequate muscle relaxant dosage was verified by the lack of a twitch response to median nerve stimulation using a peripheral nerve stimulator. Anaesthesia was provided throughout the experiment using a 250 mcg intravenous bolus of fentanyl followed by a continuous fentanyl infusion of 25 mcg/kg/hr. A minimum of two and one half hours elapsed following ketamine and xylazine administration before beginning the study. Bilateral 1.0 cm parietal burrholes were made with a hand-held twist drill. A seven-french balloon-tipped catheter was inserted into the epidural space over the right temporoparietal cortex. After evacuation of all air from the epidural balloon system, the inflation port was attached to a 3 ml salinefilled syringe for simulation of an epidural mass lesion. A 1.5 mm soft multi-ported rubber catheter was placed in the subdural space over the left temporoparietal region and the dura sealed around the catheter with a purse-string suture. This catheter was used to transduce the ICP. The burrholes then were sealed using a self-hardening acrylic compound. The animals then were randomly assigned to receive one of four intravenous injections:
(1) atracurium 0.6 mg/kg in 3 ml (n = 4); (2) vecuronium 0.2 mg/kg in 3 ml (n = 4); (3) suxamethonium 1.5 mg/kg in 3 ml (n = 4); TIME POST·INFUSION OF DRUG, seconds Prior to administration of the drug being tested, an intracranial elastance curve was produced using the epidural balloon to increase intracranial volume. The balloon was inflated with saline in 0.2 ml increments every 15 seconds until the balloon volume was 3 ml or ICP exceeded 20 mmHg. Three points on the elastance curve were recorded: (1) baseline ICP (Po), (2) ICP at the inflection point of the elastance curve (Pi) , and (3) an ICP identified on the 'steep' portion of the elastance curve (Pmax). HR, BP, and ICP were monitored continuously following administration of each agent using a Gould 2800s recorder. The ICP was allowed to plateau following balloon inflation. Each agent was given at ICP = Po, elapsed between each injection and each animal received only one drug. In addition to the values measured, CPP was calculated for each series of measurements. The animals were studied for 120 seconds following injection and the following values were used for statistical comparisons between groups: (l) variables at baseline ICP (Po, Pi, or P max);
(2) variables at 30, 60, and 120 seconds after drug administration. In addition, if any identifiable changes occurred in BP or ICP following drug infusion, the following were used: (3) all values when BP was at its minimum; (4) all values when BP was at its maximum; (5) all values when ICP was at its minimum; (6) all values when ICP was at its maximum. Multifactor analysis of variance was performed for each of ICP, CPP and MAP. The levels for each variable were time, initial ICP and muscle relaxant group, resulting in 48 sets of measurements at three points in the experiment. Kruskal-Wallis one-way analysis by ranks was used to compare the drug effects among groups at the different baseline ICPs (Po, Pi, and Pmax)· A P-value < 0.05 was considered statistically significant.
RESULTS
The response of ICP, BP and CPP to the administration of each agent when the initial ICP = Po, Pi and P max is demonstrated in Tables 1-3. Atracurium, vecuronium and placebo produced no significant effect on ICP, BP, or CPP at any baseline ICP. Atracurium produced a small increase in heart rate (peak increases of 7, 5 and 3 beats per minute at initial ICP = Po, Pi and P max respectively), but this increase was not statistically significant. Vecuronium produced complete neuromuscular blockade by 87 ± 6s whereas atracurium produced complete blockade in 75 ± lIs (defined as 0/4 twitch-response using a nerve stimulator over the median nerve). Suxamethonium produced neuromuscular blockade more quickly (49 ± 8s; P= 0.0003 versus vecuronium; P = 0.009 versus atracurium).
Unlike the nondepolarising muscle relaxants tested, suxamethonium affected both ICP and BP. The response of each animal receiving suxamethonium is demonstrated in Tables 4-6. Changes of ICP and BP from baseline are shown graphically in Figures 1 and 2. The ICP fell briefly within 30s of administration, reaching a nadir at 33 ± 2s.
The extent of the fall was proportional to the baseline ICP elevation and was statistically significant (P = 0.0001). The ICP rose quickly to levels above baseline, and again the extent of the ICP response varied directly with the elevation of baseline ICP. ICP remained within 1.0 mmHg of baseline following atracurium, vecuronium, or placebo administration, irrespective of the 'initial ICP.
Following suxamethonium infusion, a fall in BP followed the initial decline in ICP with MAP reaching a nadir at 44 ± 3s. The decline in MAP was statistically sIgnificant (P= 0.0001) and was proportional to the baseline ICP (Table 2 ; Ll MAP = 6 ± 2 (Po); 7 ± 1 (Pi); and 8 ± 2 (P max) mmHg). The mean HR did not change significantly.
The fall in MAP coincided with the rise in ICP following suxamethonium administration, resulting in a significant fall in CPP (P < 0.0005; Figure 3 ). The mean fall in CPP was 6 ± 2 mmHg when baseline ICP was Po, 6 ± 1 mmHgat Pi and 6 ± 2 mmHg at (Table 3 ). Five of the eight tests performed using suxamethonium in the presence of an intracranial mass demonstrated a fall in CPP to the limit or below the limit of cerebral autoregulation (Table 6 ). By 91 ± 8s the ICP and BP alterations had resolved and CPP had returned to baseline. Both vecuronium and atracurium produced a small rise in BP by 60s after infusion which was not statistically significant. Since ICP did not change, CPP was augmented slightly, but not significantly. These fluctuations disappeared within two minutes (Figures 2, 3 quickly (usually within 60 seconds) and safely, making it an almost ideal drug for creating intubating conditions in an emergency. Over the past decade, however, several developments have rendered uncertain the advisability of using intravenous suxamethonium in the presence of intracranial pathology. First are numerous reports that ICP increases transiently in the first minutes after suxamethonium administration in animals and in man. I -6 Except in cats, the magnitude of the increase is usually small, fueling a debate over the clinical significance of this effect. Second, newer nondepolarising muscle relaxants, atracurium and vecuronium, have been developed whose action is fairly rapid in onset (60 to 90s when high dose administration follows a priming dose) and also are quite safe. 9 -11 ,15 The effects of atracurium and vecuronium on intracranial haemodynamics have not been described. The only study which graphically demonstrates the effect ofsuxamethonium on ICP over time in man was published in 1986 rapid ICP rise and serves as a model for a rapidly expanding intracranial mass. Nothing can be inferred from this study regarding suxamethonium's effect when a slowly growing or expanding mass lesion is present. Compensatory responses already functioning to moderate ICP may blunt this effect. by Minton et al_ 6 The biphasic nature and the magnitude of its effect on ICP which we demonstrate in swine are almost identical to those seen in man, although the onset of the ICP fall and subsequent rise occur somewhat earlier in this animal model. The early depression of MAP, coupled with the increase
The deleterious effects of suxamethonium on CPP is due to its influence both on ICP and BP. This is important for two reasons. (1) There has been a tendency to dwell on ICP in ICP, results in a significant decline in CPP. This effect on BP was described by Minton et al, 6 and McLeskey et al, 5 in man. Unfortunately, no study in man has evaluated the magnitude of these effects in relation to intracranial pressure or elastance at the time of suxamethonium administration. In this study an intracranial pressure-volume curve was established prior to drug administration '" to determine an epidural mass size (balloon volume) which would increase ICP to the '" inflection point (Pi) and to a point (P max) on ~ this curve where intracranial elastance was ~ very poor. It was clear that the magnitude of 13 the effect on ICP and CPP increased with increasing elastance (Ll ICPILl balloon volume). However, these effects were small and transient. In patients who are haemodynamically stable with normal or mildly evaluated ICP there should be little concern over the use of suxamethonium. Indeed, these changes are less substantial than those produced by stimulatory manoeuvres such as airway suctioning or endotracheal intubation. These data infer, however, that subjects who can least tolerate rapid fluctuations of ICP and CPP, such as those with severe closed head injury or rapidly expanding intracranial hematomata, are more There is a 10 to 15% fall in BP, even with vecuronium premedication,6 just as was demonstrated with this model. Neither atracurium nor vecuronium produced BP, ICP or CPP changes when compared with placebo. Intubating doses were used which are the same as those used in man, and the time required for neuromuscular blockade was similar to that seen in man when using these drugs. Although suxamethonium provided complete loss of the twitch response 25 to 30s (atracurium) and 35 to 40s (vecuronium) sooner than the nondepolarising relaxants, this small difference is not relevant clinically except in cases where active vomiting or loss of the airway due to facial trauma requires very rapid endotracheal intubation. If elective procedures are performed or if bag-mask oxygenation and ventilation can sustain a patient following trauma for those few additional seconds, the potential morbidity of the fall in CPP may be avoided.
In conclusion, in a swine model, suxamethonium administration results in a biphasic ICP response, with an early decline followed by a rapid rise. The ICP rise is accompanied by a fall in BP, which together depress CPP. This response is transient, lasting less than 90s. The magnitude of these effects is directly proportional to the ICP when the drug is given. Neither atracurium nor vecuronium affect BP, ICP or CPP in this model. Although suxamethonium acted more quickly, atracurium and vecuronium produced complete twitch suppression quickly and safely, and may be preferred for patients with known or suspected intracranial hypertension and marginal cerebral perfusion pressure.
